Pioneering Gene Therapy for CNS proteinopathy Alzheimer's, Parkinson's, Huntington's disease, and amyotrophic lateral sclerosis (ALS)
Central nervous system (CNS) proteinopathies, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), are characterized by the misfolding and aggregation of proteins, leading to cellular dysfunction and progressive tissue damage. These debilitating diseases affect millions worldwide, and current treatments largely focus on managing symptoms rather than addressing the underlying cause.
At Canary, we are revolutionizing the treatment of CNS proteinopathies by harnessing the power of gene therapy and targeted antibodies. Our unique approach aims to:
Halt disease progression
We utilize innovative gene therapy techniques to correct the underlying genetic defects that contribute to protein misfolding.
Reduce protein accumulation
We deploy targeted antibodies to selectively remove misfolded proteins, preventing further damage to neurons.
Pioneering Gene Therapy and Precision Diagnostics
Our mission is to harness the transformative power of gene therapy and AI-driven precision diagnostics to revolutionize healthcare and empower individuals to live healthier, longer lives. We are pioneering a novel approach to vectorized gene therapy with the aim of providing a single-dose comprehensive and lasting solution to diseases and conditions that currently have few options.
Disclaimer: Canary Global Inc.’s website includes future planned care offerings, that are currently in development and are subject to regulatory approval before they are able to be commercialized